{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Cedars-Sinai
Cedars-Sinai
  • Sign In
  • Live Activities
  • Internal Series
  • On-Demand Activities
  • CE Planning Process
  • Calendar
  • Help
Close Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Use My Cedars Login
Login with my CloudCME™ account
Enter your email and password to login:

*
*
Login

New to CloudCME? Create an Account:

Create New Account
Forgot Your Password?

Login Tips: 
PLEASE CREATE AN ACCOUNT IF:

• You have never attended a Cedars-Sinai CE activity
• OR You are a NEW member of the Cedars-Sinai Medical Staff since August 2023

If you do NOT meet either of the criteria above, please DO NOT CREATE AN ACCOUNT:

• If you do not know which email address is used for your account, please contact the Cedars-Sinai Office of CME.
• Accounts for existing Cedars-Sinai Medical Staff (prior to August 2023) use the primary email on file with the Medical Staff Office.

For ALL USERS: If you do not have the password for your account, click the "Forgot Your Password?" link.

Forgot Your Password?







Back to Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Email is required Invalid: Enter valid email address
First Name is required
Last Name is required
Password is required


Password Requirements

  • Must be between 8 and 16 characters in length
  • Must Contain at least 1 upper case character
  • Must Contain at least 1 lower case character
  • Must contain at least 1 numeric character
  • Must contain at least 1 of the following ! * @ # $ % ^ & + =
Confirm password

Passwords must match
Password must be between 8 and 16 characters and contain the following:
•at least 1 upper case character
•at least 1 lower case character
•at least 1 numerical character
•at least 1 special character

  • -- Select Degree --
  • ATC
  • BSN
  • CCC-SLP
  • CCLS
  • CPhT
  • CRNA
  • CRT
  • DC
  • DDS
  • DMD
  • DNAP
  • DNP
  • DO
  • DPM
  • LCGC
  • LCSW
  • LVN
  • MBBCh
  • MBBS
  • MD
  • MD, PhD
  • MPH
  • MS
  • MSN
  • MSW
  • None
  • NP
  • OT
  • Other
  • OTR/L
  • PA
  • PharmD
  • PhD
  • PsyD
  • PT
  • RD
  • RN
  • RN, BSN
  • RPh
  • RRT
  • RT
  • RVT
Degree is required
Please enter your degree:
You must enter a degree

Profession is required




Back to Login
Close Search Site Search: Enter your search terms in the field below to view results.

please enter a term to search
Close Specialties
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##

10th Annual New Therapeutics in Oncology: The Road to Personalized Medicine Featuring The Fenmore Lectureship and The Redlich Lectureship


10th Annual New Therapeutics in Oncology: The Road to Personalized Medicine Featuring The Fenmore Lectureship and The Redlich Lectureship Banner

  • Overview
  • Register
  • Faculty
  • Schedule
  • Brochure
  • Exhibitor Registration
  • View Exhibits
Add to Calendar 10th Annual New Therapeutics in Oncology: The Road to Personalized Medicine Featuring The Fenmore Lectureship and The Redlich Lectureship 11/12/2021 2:00:00 PM 11/13/2021 4:30:00 PM America/Los_Angeles For More Details: https://cedars.cloud-cme.com/oncologycme21 Description: This important educational activity will provide guidance to front-line and oncology clinicians, nurses, physicians, pharmacists, nurse practitioners, physician assistants and pharmacists, with the most current information available about new agents in oncology and translating of the latest research to their patients. The conference will cover drug and treatment updates with a focus on myeloma, gynecological malignanci... Sofitel Los Angeles at Beverly Hills, 8555 Beverly Boulevard false MM/DD/YYYY


Date & Location
Friday, November 12, 2021, 2:00 PM - Saturday, November 13, 2021, 4:30 PM PST, Sofitel Los Angeles at Beverly Hills, 8555 Beverly Boulevard

Target Audience
Specialties - Hematology, Internal Medicine, Oncology, Pain Management, Radiation Oncology, Surgery

Overview
This important educational activity will provide guidance to front-line and oncology clinicians, nurses, physicians, pharmacists, nurse practitioners, physician assistants and pharmacists, with the most current information available about new agents in oncology and translating of the latest research to their patients. The conference will cover drug and treatment updates with a focus on myeloma, gynecological malignancies, hematologic malignancies, sarcoma, bladder cancer and GI malignancies. The conference features a comprehensive review of new drugs approved along with their mechanism of action, next generation CAR cell therapies and a keynote lecture outlining advances in immunotherapy. Next generation studies will also be addressed, and the conference will offer participants a session designed to provide insight into the latest advances in lung cancer treatment, including integration of new molecularly-targeted therapies and immunotherapy.

Objectives
  1. Evaluate new, emerging and novel therapeutic agents, advances in care, and clinical trials data and apply relevant findings into the management of cancer patients
  2. Develop personalized treatment plans for patients based upon an evaluation of efficacy and safety of current and newly approved agents and therapeutic options
  3. Integrate appropriate strategies into clinical practice to optimize the management of patients with gynecologic malignancies to improve patient outcomes
  4. Utilize AJCC or other appropriate staging in clinical practice, including appropriate prognostic indicators and evidence-based national guidelines for treatment planning
  5. Anticipate the needs and issues of cancer survivors and develop an individualized wellness plan in partnership with cancer survivors, their families and the healthcare team

Registration

Physicians: $129
Pharmacists: $79
Industry: $229
Healthcare professionals-Nurses, Residents/Fellows, Medical students, C-S associated healthcare professionals:Free

Refund Policy
All cancellations must be submitted in writing and refunds will be subject to an administrative charge. To view the policy, click here. Please e-mail cancellation request to [email protected]. If you do not receive confirmation of your cancellation via e-mail, please call (310) 423-5548.  

Disclaimer
All educational materials provided during and after the course are for your personal use only and should not be reproduced or distributed in any manner without the express permission of Cedars-Sinai.

Right to Cancel or Postpone
Cedars-Sinai reserves the right to cancel or postpone any course due to unforeseen circumstances. In the unlikely event that Cedars-Sinai must cancel or postpone this course, the registration fee will be fully refunded. Cedars-Sinai is not responsible for any related costs, charges or expenses to participants, including fees assessed by airline, travel or lodging agencies.

Health and Safety Protocol
Before registering for this event, please read our Health and Safety Protocol for current requirements pertaining to attending in-person events.


Accreditation

Cedars-Sinai Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Cedars-Sinai Medical Center designates this Live Activity for a maximum of 10.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Non-Physician Attendance
A certificate of participation will be provided to other health care professionals requesting credits. Participants should ensure in advance that their credentialing or licensing organization accepts AMA PRA Category 1 Credits™.

American Board of Internal Medicine (ABIM) MOC Recognition Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Credits
AMA PRA Category 1 Credit(s)™ (MD, DO) (10.00 hours), ABIM MOC Part 2 (10.00 hours), Non-Physician AMA Attendance (10.00 hours)


Keywords: LIVEABIM2AMAMOC



Mitigation of Relevant Financial Relationships


Cedars-Sinai adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Member Information
Role in activity
Nature of Relationship(s) / Name of Ineligible Company(s)
Robert A. Figlin, MD
Cedars-Sinai
Course Director, Faculty
Nothing to disclose
Razelle Kurzrock, MD
Medical College of Wisconsin
Course Director, Faculty
Dr. Kurzrock has received research funding from Biological Dynamics, Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, and TopAlliance; as well as consultant and/or speaker fees and/or advisory board for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Biological Dynamics, EISAI, EOM Pharmaceuticals, Iylon, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc., CureMetrix, and IDbyDNA; serves on the Board of CureMatch and CureMetrix,and is a co-founder of CureMatch.-Relationship_has_not_ended
Faculty Photos
Alain Mita, MD
Cedars-Sinai
Course Director, Faculty
Contracted Research-Astellas Pharma US, Inc. Roche - Genentech Bristol-Myers Squibb Company Five Prime Therapeutics, Inc. Xencor Qurient Co. Ltd. ALX Oncology, Inc. Fusion Pharmaceuticals Gilead Sciences, Inc. Kezar Life Sciences Astex Pharmaceuticals, Inc. BioNTech Pfizer Inc., U.S. Pharmaceuticals Group Southwest Oncology Group IMV Inc Janssen R&D LLC Astra Zeneca, L.P. Molecular Template, Inc. Mundipharma - EDO GmbH
Faculty Photos
Monica M. Mita, MD
Cedars-Sinai
Course Director, Faculty
Contracted Research-Boehringer Ingelheim Pharmaceuticals, Inc. Tesaro Alliance Sanofi-Aventis Astex Pharmaceuticals, Inc. Pfizer Inc., U.S. Pharmaceuticals Group BeiGene Hoffman-La Roche Medivir AB Astra Zeneca, L.P. Merus Southwest Oncology Group Seagen (Seattle Genetics, Inc.) Amphivena Therapeutics Hummingbird Bioscience Immix Biopharma, Inc. Spring Bank Pharmaceuticals Changchun Intellicrown Pharmaceutical Co., Ltd Daiichi Sankyo Genzada Pharmaceuticals Incyte Corporation Kronos Bio Linnaeus Therapeutics, Inc. AbbVie Minneamrita Therapeutics, LLC Molecular Template, Inc. Oxford Bio Therapeutics Rgenix, Inc. SQZ Biotechnologies Tizona Therapeutics HiberCell, Inc Jounce Therapeutics Syros Pharmaceuticals, Inc Theratechnologies Inc. NeuPharma, Inc.
Faculty Photos
Ani Balmanoukian, MD
The Angeles Clinic
Faculty
Speaker-Bristol-Myers Squibb|Speaker-AstraZeneca|Speaker-Genentech, Inc.
Faculty Photos
Reva Basho, MD
Cedars-Sinai
Faculty
Consultant-Genomic Health (Relationship has ended)|Consultant-AstraZeneca (Relationship has ended)|Consultant-Biotheranostics (Relationship has ended)|Consultant-Pfizer, Inc. (Relationship has ended)|Speaker-Genentech, Inc. (Relationship has ended)|Speaker-Seattle Genetics|Other: Honoraria-MJH Healthcare (Relationship has ended)|PrincipalNamedInvestigator-Seattle Genetics|PrincipalNamedInvestigator-Merck and Company, Inc.|PrincipalNamedInvestigator-Eli Lilly and Company|PrincipalNamedInvestigator-Takeda Pharmaceuticals, Inc.
Faculty Photos
John Chute, MD
Cedars-Sinai
Faculty
Nothing to disclose
Faculty Photos
Jun Gong, MD
Cedars-Sinai
Faculty
Advisor-EMD Serono (Relationship has ended)|Advisor-Elsevier|Advisor-Exelixis (Relationship has ended)|Advisor-QED Therapeutics (Relationship has ended)|Advisor-Natera (Relationship has ended)|Advisor-Bayer Corporation (Relationship has ended)|Advisor-Basilea (Relationship has ended)|Advisor-HalioDx (Relationship has ended)|Advisor-Eisai, Inc. (Relationship has ended)|Advisor-Janssen (Relationship has ended)|Advisor-Aveo (Relationship has ended)
Aaron Goodman, MD
UC San Diego Health
Faculty
Consultant-Seattle Genetics|Consultant-EUSA Pharma|Advisor-Shoreline (Relationship has ended)
David Hoffman, MD
Cedars-Sinai
Faculty
Nothing to disclose
Kenneth H. Kim, MD, MHPE
Cedars-Sinai
Faculty
Nothing to disclose
John E. Lee, LCGC
Samuel Oschin Comprehensive Cancer Center
Faculty
Nothing to disclose
Faculty Photos
Philomena McAndrew, MD
Cedars Sinai
Faculty
Nothing to disclose
Joyce O'Shaughnessy, MD
Baylor-Sammons Cancer Center
Faculty
Consultant-Abbvie|Consultant-Amgen|Consultant-Aptitude Health|Consultant-AstraZeneca|Consultant-Bayer Corporation|Consultant-Bristol-Myers Squibb|Consultant-Celgene|Consultant-Daiichi Sankyo|Consultant-Eisai, Inc.|Consultant-Genentech, Inc.|Consultant-G1 Therapeutics|Consultant-Gilead Sciences|Consultant-Immunomedics|Consultant-Ipsen Pharma|Consultant-Eli Lilly and Company|Consultant-Merck and Company, Inc.|Consultant-Myriad|Consultant-Novartis AG|Consultant-Ontada|Consultant-Pfizer, Inc.|Consultant-Pierre Fabre|Consultant-Puma Biotechnology|Consultant-Prime Oncology|Consultant-Roche|Consultant-Samsung Bioepis|Consultant-Sanofi-Aventis|Consultant-Seagen|Consultant-Takeda Pharmaceuticals, Inc.
Faculty Photos
Arsen Osipov, MD
Cedars-Sinai
Faculty
Nothing to disclose
Faculty Photos
Sukhmani Padda, MD
Cedars-Sinai
Faculty
PrincipalNamedInvestigator-Epicentrx (Relationship has ended)|PrincipalNamedInvestigator-Bayer Corporation (Relationship has ended)|PrincipalNamedInvestigator-Boehringer Ingelheim Vetmedica GmbH (Relationship has ended)|Advisor-Janssen Pharmaceuticals|Advisor-Sanofi-Aventis|Advisor-Mirati Therapeutics|Speaker-OncLive (Relationship has ended)|Consultant-Jazz Pharmaceuticals (Relationship has ended)|Consultant-Physician Education Resource (PER) (Relationship has ended)|Advisor-Genentech, Inc. (Relationship has ended)|Independent ContractorResearcher-Nanobiotix (Relationship has ended)|Advisor-AstraZeneca|Advisor-G1 Therapeutics (Relationship has ended)|Advisor-Blueprint (Relationship has ended)|Speaker-California Consortium/MECC Global Meetings (Relationship has ended)
Lawrence Piro, MD
The Angeles Clinic and Research Institute
Faculty
Nothing to disclose
Zachary Zumsteg, MD
Cedars-Sinai
Faculty
Nothing to disclose
Bethany Wendel, RN
Cedars-Sinai
Planner
Nothing to disclose
Hilary Lachoff, RN
Cedars-Sinai
Planner (old label)
Nothing to disclose

Friday, November 12, 2021
Afternoon Session Moderators: Lawrence Piro, MD and Monica Mita, MD
2:00PM - 5:00PM
Welcome and Introductory Remarks
2:00PM - 2:10PM
Alain Mita, MD
Monica M. Mita, MD
Robert A. Figlin, MD
Therapeutic Implications of Germline Testing in Patients with Advanced Cancers
2:10PM - 2:40PM
John E. Lee, LCGC
Q&A
2:40PM - 2:50PM
John E. Lee, LCGC
Pancreatic cancer treatment in 2021 and beyond
2:50PM - 3:20PM
Arsen Osipov, MD
Q&A
3:20PM - 3:30PM
Arsen Osipov, MD
Expert updates for treatment of gynecological malignancies
3:30PM - 4:00PM
Kenneth H. Kim, MD, MHPE
Q&A
4:00PM - 4:10PM
Kenneth H. Kim, MD, MHPE
Deintensification strategies for the treatment of HPV-positive Head and Neck cancer: is less more?
4:10PM - 4:40PM
Zachary Zumsteg, MD
Q&A
4:40PM - 4:50PM
Zachary Zumsteg, MD
Cocktail/Reception
5:00PM - 6:00PM
Saturday, November 13, 2021
Morning Session Moderators: Robert A Figlin, MD and Philomena McAndrew, MD
8:00AM - 12:30PM
New drugs approved in 2021 and their mechanism of action
8:00AM - 8:40AM
Alain Mita, MD
Q&A
8:40AM - 8:50AM
Alain Mita, MD
Updates on new therapeutics for hematologic malignancies
8:50AM - 9:20AM
Aaron Goodman, MD
Q&A
9:20AM - 9:30AM
Aaron Goodman, MD
Precision genomics and immunotherapy: N-of-one personalized therapy
9:30AM - 10:00AM
Razelle Kurzrock, MD
Q&A
10:00AM - 10:10AM
Razelle Kurzrock, MD
Break
10:10AM - 10:30AM
Expert opinion for new therapeutic approaches in HR+ breast cancer
10:30AM - 11:00AM
Joyce O'Shaughnessy, MD
Q&A
11:00AM - 11:10AM
Joyce O'Shaughnessy, MD
Immunotherapy for cancer treatment: what is new and what’s coming?
11:10AM - 11:40AM
Ani Balmanoukian, MD
Q&A
11:40AM - 11:50AM
Ani Balmanoukian, MD
Recent advances in bladder cancer treatment
11:50AM - 12:20PM
Jun Gong, MD
Q&A
12:20PM - 12:30PM
Jun Gong, MD
Lunch
12:30PM - 1:30PM
Afternoon Session Moderators: Razelle Kurzrock, MD
1:30PM - 4:30PM
KEYNOTE PRESENTATION: Advances in Cellular Therapy
1:30PM - 2:20PM
John Chute, MD
Q&A
2:20PM - 2:30PM
John Chute, MD
Integrating precision medicine in RCC treatment. Are we there yet?
2:30PM - 3:00PM
Robert A. Figlin, MD
Q&A
3:00PM - 3:10PM
Robert A. Figlin, MD
Expert opinion for new therapeutic approaches in Her-2-positive breast cancer
3:10PM - 3:40PM
Reva Basho, MD
Q&A
3:40PM - 3:50PM
Reva Basho, MD
Lung cancer treatment as paradigm for precision medicine
3:50PM - 4:20PM
Sukhmani Padda, MD
Q&A
4:20PM - 4:30PM
Sukhmani Padda, MD

Please Click here to view the Exhibit prospectus: 10th Annual New Therapeutics in Oncology: The Road to Personalized Medicine Featuring The Fenmore Lectureship and The Redlich Lectureship

 

10th Oncology Posting by Cedars-Sinai CME
Contact Us:
CME Office
Cedars-Sinai
8700 West Beverly Blvd., CME
Los Angeles, CA 90048
Phone: 3104235548
Email: [email protected]
Website: https://cedars.cloud-cme.com

Exhibit at this Event

Exhibitor Packages

Exhibitor Package - Gold Level Price: $2200.00
Includes:
  • Recognition as a Gold Level Supporter Exhibitor
  • (1) 6ft Table Top, includes 2 chairs
  • Number of Exhibitor Badges: 2
  • (2) Complimentary breakfast, lunch and refreshment
  • Exhibit Location: Assigned Table Space

Deadline for order commitment is 11/15/2021 12:00:00 AM.

Exhibitor Package - Silver Level Price: $1000.00
Includes:
  • Recognition as a Silver Level Supporter Exhibitor
  • Posting on Meeting Sponsor Page
  • Number of Exhibitor Badges: 0
  • Posting Company information on Conference website

Deadline for order commitment is 11/15/2021 12:00:00 AM.

10th Annual New Therapeutics in Oncology: The Road to Personalized Medicine Featuring The Fenmore Lectureship and The Redlich Lectureship

 

10th Oncology Posting by Cedars-Sinai CME


CE Disclosure Form  | CE Application  | Privacy  |  Cedars-Sinai CME Homepage

Contact Us: [email protected]

        

© 2025 Cedars-Sinai. All Rights Reserved. A 501(c)(3) non-profit organization.